{"name":"Oncternal Therapeutics","slug":"oncternal","ticker":"ONCT","exchange":"NASDAQ","domain":"oncternal.com","description":"Oncternal Therapeutics is a biopharmaceutical company focused on developing therapies for patients with cancer. The company's pipeline includes several clinical-stage programs targeting various oncology indications. Oncternal's lead product, cirmtuzumab, is being investigated for the treatment of mantle cell lymphoma and other B-cell malignancies. The company is also developing TK216, a small molecule inhibitor of CDK9, for the treatment of various cancers.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"James Breitmeyer","sector":"Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":785000,"revenueGrowth":-47.3,"grossMargin":0,"rdSpend":0,"netIncome":-39479000,"cash":36729000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-01","label":"Zilovertamab Phase 3 readout (Lymphoma, Mantle-Cell, Lymphoma)","drug":"Zilovertamab","drugSlug":"zilovertamab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-09-24","label":"Zilovertamab Phase 2 readout (DLBCL, Diffuse Large B-Cell Lymphoma)","drug":"Zilovertamab","drugSlug":"zilovertamab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-03-29","label":"Zilovertamab Phase 3 readout (Diffuse Large B-Cell Lymphoma)","drug":"Zilovertamab","drugSlug":"zilovertamab","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-06-01","label":"cirmtuzumab patent cliff ($0.0B at risk)","drug":"cirmtuzumab","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"TK216 patent cliff ($0.0B at risk)","drug":"TK216","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Zilovertamab","genericName":"Zilovertamab","slug":"zilovertamab","indication":"Other","status":"discontinued"}]}],"pipeline":[{"name":"Zilovertamab","genericName":"Zilovertamab","slug":"zilovertamab","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Oncternal Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Oncternal reported its fourth quarter and full year 2023 financial results, including revenue of $1.4 million and a net loss of $24.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-18","type":"deal","headline":"Oncternal Therapeutics Announces Collaboration with Merck to Develop Combination Therapy for Cancer","summary":"Oncternal entered into a collaboration with Merck to develop a combination therapy for cancer, leveraging Oncternal's cirmtuzumab and Merck's pembrolizumab.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"Oncternal Therapeutics Announces Positive Interim Results from Phase 1/2 Clinical Trial of Cirmtuzumab in Patients with Mantle Cell Lymphoma","summary":"Oncternal reported positive interim results from its Phase 1/2 clinical trial of cirmtuzumab in patients with mantle cell lymphoma, demonstrating encouraging efficacy and safety.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPNlBZRHB4V2NDZExTTzNORlhvaVNBWDVYOGtXMUxNNEduX3JyRUhBTHkzZG1BMkRWSnh3SjBMSnc5NWNXOTBEUWVoRFVZcWpNcmoxOExSVC1hNDNONXktSVMySm9mN3Z2TWx2M0o1TnZKQjNoNXZWZ01ZQnQ5WGpoWjYtLW13VU9CMjdIS29TV0Rxeno0N09kbkpkdGVNRkxkTU11MkF3?oc=5","date":"2025-07-01","type":"pipeline","source":"Pharmaceutical Technology","summary":"Oncternal sells assets for up to $68m and calls it quits - Pharmaceutical Technology","headline":"Oncternal sells assets for up to $68m and calls it quits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPNDFXc20wLUdYUE1RblFtOGwxZjJTbW5aUGVOX2xIb2ZJbnRfMWVWNFFMTGwxSmU5VS1uaktWZmhadWt0QmRQOVUtTk1abkJkQ0wxeHJRZllqOE5sazFuNWZPeV9EalFnaDIteFVrTHB3ajF2RmtZT3BiZXBNOGZrNmtyYVVuQ0lnTG5TQVZFUEhFQXJKOFRaVU8yQU9qR3RXa282bjdFX01IR3V0Q0htUVN4TUsyNFhjMkZMZG9B?oc=5","date":"2025-03-07","type":"pipeline","source":"Stock Titan","summary":"From Nasdaq to Dark: What's Next for Oncternal After March 2025 Delisting? - Stock Titan","headline":"From Nasdaq to Dark: What's Next for Oncternal After March 2025 Delisting?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQTEhLeEFQWmhvYzBURUJTbEZkSGxjeTRuU0hvUlhKQ2VTWnJBcVJCbGpCR3dfeElueC1NTldkT1ZSNHd0bkZJR0dJZW5tMjVfdC1iNmEybnFubkk3d0pOUEFEcm9jTmVQT2VPaFVqdXpFY1NxMnFrQUhtNVNBSHNkRHcwMFJSbUJrdENPS2N4bnZaalhfSkxrMUFBajFoZnNl?oc=5","date":"2024-11-25","type":"pipeline","source":"Investing.com","summary":"Oncternal shares to be delisted from Nasdaq - Investing.com","headline":"Oncternal shares to be delisted from Nasdaq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNQ21uNDFkZHk4amkwT1pwWFlKbEVMUC1ZUGdVUGhiZ1ZOajNzSkc0VG52bktzT2xDM3llLTFfQlJxWWp0X1djYlJObGpncHV5Y3JfbGNSUkdsMGNhZ2lUYmt3MEluRFAyRHRyNWNLcTd3VEtYM3dManJ6ZHZhaTk0OXBubE1nWm1mZnlBZV9rNzhzcEtxSnJmenc1Y0ZFRWZVaVNFOGdPbExUbFA4T09GZWdYTDVsX0U?oc=5","date":"2024-09-13","type":"trial","source":"Pharmaceutical Technology","summary":"Oncternal stock crashes by 60% as it lays off staff and scraps trials - Pharmaceutical Technology","headline":"Oncternal stock crashes by 60% as it lays off staff and scraps trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxORGo5LUwzT0twX2Z4SVJwdFdtUWI3ZU13Mi1qZXlSdFZqaWZwblhYeVlyeHI1b25NWkdFNHZGQlBYdV9Ga1U4Wm93X1YxVkFZWm9uZ0dUUnVPbDVkdEFIWGdZUk5aajlOR21YRDlpV2VxbUNUUlRVNVQxRXQxa1RxTXFIN3plejViLWkzLVhaSmRYSjc0RG9DYUl4RDZQM3l1dzVnOEFfalVabG9rNmhGMGM2cE0?oc=5","date":"2024-09-12","type":"trial","source":"Fierce Biotech","summary":"Oncternal folds all clinical trials after lackluster data drop, patient death - Fierce Biotech","headline":"Oncternal folds all clinical trials after lackluster data drop, patient death","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPN3ZzZW1QSVhBTmFfMF9pTEUtYjBQenY0bmJiWE53Yk03Wmx0NEt5aHIwd2dLalotZEx1NnpaMDZiLVlzekNpRFhmZ2ZweWpKanNNbXBNZzZ5dGhYRmRhcERtamUtRXAyQlpMd0s5cUdHWUhLSFRjaFBDM2lEMlZzM1FyMDRDdk5lbERTVDFZMW5pb3hXdmtCMzNMOWZGREN1S0hxT0ZzcnZUMV9WdE5z?oc=5","date":"2023-12-28","type":"trial","source":"Fierce Biotech","summary":"Oncternal Therapeutics reports patient death in CAR-T dose-escalation study - Fierce Biotech","headline":"Oncternal Therapeutics reports patient death in CAR-T dose-escalation study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTFBQTUJMN3JHSmlXWGJSQndnRDVSUkFENmdRZ2FIZlVUSFNqTVR4NXltYWJvbDJ2TVg0MDJkZmhCVzFBSlowcHJkVDVvekdTdw?oc=5","date":"2020-11-07","type":"pipeline","source":"Stock Titan","summary":"Latest ONCT News - Oncternal Therapeutics Announces the Sale o... - Stock Titan","headline":"Latest ONCT News - Oncternal Therapeutics Announces the Sale o...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9ZQ3R2Tl9WYk5QdDRaMW93QjR6Vi1YcWZhT1JNYVJEVTZlMXhuXzk1dFU3N1lZUlFoUFpjZnZYeUJDYWZBWmZQUzhHeWt1WU00ODlFOUJJTWtua04ycnc?oc=5","date":"2020-11-04","type":"earnings","source":"Stock Titan","summary":"Latest ONCT News - Oncternal Announces Third Quarter 2020 Fina... - Stock Titan","headline":"Latest ONCT News - Oncternal Announces Third Quarter 2020 Fina...","sentiment":"neutral"}],"patents":[{"drugName":"cirmtuzumab","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"TK216","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"discontinued":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Bristol Myers Squibb","Merck & Co."],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":785000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":785000,"period":"2023-12-31"},{"value":1490000,"period":"2022-12-31"},{"value":1490000,"period":"2022-12-31"},{"value":4315000,"period":"2021-12-31"},{"value":4315000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":0,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-39479000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":36729000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}